-
公开(公告)号：US12103960B2
公开(公告)日：2024-10-01
申请号：US17314503
申请日：2021-05-07
发明人： William Olson , Joel Martin , Neil Stahl , Jee Kim
CPC分类号： C07K14/71 , A61P27/02 , A61K38/00 , C07K2317/53
摘要： Vascular endothelial growth factor (VEGF) traps and VEGF mini-traps that include VEGF receptor Ig-like domains, fused to a multimerizing component, are disclosed. The VEGF traps and VEGF mini-traps bind to VEGF and block its interaction with the VEGF receptor. Such molecules are useful for treating angiogenic eye disorders (e.g., age-related macular degeneration), cancer and for other undesired angiogenesis.
-
公开(公告)号：US20240124554A1
公开(公告)日：2024-04-18
申请号：US18482589
申请日：2023-10-06
发明人： William OLSON , Joel Martin , Neil Stahl , Jee Kim
摘要： The present relates to VEGF traps and VEGF mini-traps that include VEGF receptor Ig-like domains, fused to a multimerizing component, which bind to VEGF and block its interaction with the VEGF receptor. Such molecules are useful for treating angiogenic eye disorders (e.g., age-related macular degeneration), cancer and for other undesired angiogenesis.
-
公开(公告)号：US11191844B2
公开(公告)日：2021-12-07
申请号：US15738801
申请日：2016-07-06
发明人： Julian Andreev , Nithya Thambi , Frank Delfino , Joel Martin , Gavin Thurston , Katherine Cygnar , Nicholas Papadopoulos
IPC分类号： A61K47/68 , C07K16/22 , C07K16/28 , C07K16/32 , C07K16/18 , C07K14/47 , C07K16/30 , A61P35/00 , C07K16/46 , A61K39/00 , C12N9/64 , C07K16/12
摘要： The present disclosure provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present disclosure can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the disclosure, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present disclosure results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the disclosure, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present disclosure causes or facilitates the targeted killing of tumor cells.
-
公开(公告)号：US20200154684A1
公开(公告)日：2020-05-21
申请号：US16625168
申请日：2018-06-27
发明人： Alexander O. Mujica , Viktoria Gusarova , Cheng Wang , Christos Kyratsous , Terra Potocky , Katherine Cygnar , Joel Martin
IPC分类号： A01K67/027 , A61K49/00 , C07K14/705
摘要： Non-human animal cells and non-human animals comprising a humanized Asgr1 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Asgr1 locus express a human ASGR1 protein or an Asgr1 protein, fragments of which are from human ASGR1. Methods are provided for using such non-human animals comprising a humanized Asgr1 locus to assess in vivo efficacy of human-ASGR1-mediated delivery of therapeutic molecules or therapeutic complexes to the liver and to assess the efficacy of therapeutic molecules or therapeutic complexes acting via human-ASGR1-mediated mechanisms.
-
公开(公告)号：US11129903B2
公开(公告)日：2021-09-28
申请号：US15202822
申请日：2016-07-06
发明人： Julian Andreev , Nithya Thambi , Frank Delfino , Joel Martin , Gavin Thurston , Katherine Cygnar , Nicholas Papadopoulos
IPC分类号： A61K47/68 , C07K16/22 , C07K16/28 , C07K1/32 , C07K16/12 , C07K16/18 , C07K14/47 , C07K16/30 , A61P35/00 , C07K16/46 , A61K39/00 , C12N9/64 , C07K16/32
摘要： The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the invention, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention causes or facilitates the targeted killing of tumor cells.
-
公开(公告)号：US20220008548A1
公开(公告)日：2022-01-13
申请号：US17483588
申请日：2021-09-23
发明人： Julian Andreev , Nithya Thambi , Frank Delfino , Joel Martin , Gavin Thurston , Katherine Cygnar , Nicholas Papadopoulos
IPC分类号： A61K47/68 , C07K16/22 , C07K16/28 , C07K16/32 , C12N9/64 , C07K16/12 , C07K16/18 , C07K14/47 , C07K16/30 , A61P35/00 , C07K16/46
摘要： The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the invention, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention causes or facilitates the targeted killing of tumor cells.
-
公开(公告)号：US20190000984A1
公开(公告)日：2019-01-03
申请号：US15738801
申请日：2016-07-06
发明人： Julian Andreev , Nithya Thambi , Frank Delfino , Joel Martin , Gavin Thurston , Katherine Cygnar , Nicholas Papadopoulos
IPC分类号： A61K47/68 , C07K16/28 , C07K16/22 , C07K16/30 , C07K16/32 , C12N9/64 , A61P35/00 , C07K16/46
摘要： The present disclosure provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present disclosure can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the disclosure, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present disclosure results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the disclosure, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present disclosure causes or facilitates the targeted killing of tumor cells.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.02 秒)
